Laurus Labs Limited Stock Bombay S.E.

Equities

LAURUSLABS

INE947Q01028

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:50 2024-04-26 am EDT 5-day change 1st Jan Change
437.1 INR +2.77% Intraday chart for Laurus Labs Limited +2.55% +1.62%
Sales 2024 50.41B 605M Sales 2025 * 57.43B 689M Capitalization 230B 2.76B
Net income 2024 1.61B 19.28M Net income 2025 * 4.12B 49.46M EV / Sales 2024 4.2 x
Net Debt 2024 * 18.41B 221M Net Debt 2025 * 21.28B 256M EV / Sales 2025 * 4.37 x
P/E ratio 2024
132 x
P/E ratio 2025 *
50.1 x
Employees 5,753
Yield 2024 *
0.31%
Yield 2025 *
0.39%
Free-Float 65.41%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.77%
1 week+2.55%
Current month+11.58%
1 month+10.00%
3 months+16.78%
6 months+21.59%
Current year+1.62%
More quotes
1 week
415.20
Extreme 415.2
443.60
1 month
389.45
Extreme 389.45
470.90
Current year
358.70
Extreme 358.7
470.90
1 year
279.65
Extreme 279.65
470.90
3 years
279.65
Extreme 279.65
723.55
5 years
59.60
Extreme 59.6
723.55
10 years
59.60
Extreme 59.6
723.55
More quotes
Managers TitleAgeSince
Founder 63 05-09-18
Director of Finance/CFO - 06-11-29
Chief Operating Officer - 08-04-01
Members of the board TitleAgeSince
Founder 63 05-09-18
Chairman 83 17-05-23
Director/Board Member 68 -
More insiders
Date Price Change Volume
24-04-26 437.1 +2.77% 173 551
24-04-25 425.3 -2.09% 191,193
24-04-24 434.4 +0.32% 28,731
24-04-23 433 +0.67% 87,834
24-04-22 430.1 +0.90% 34,798

Delayed Quote Bombay S.E., April 26, 2024 at 06:00 am EDT

More quotes
Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company offers integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. The Company operates through three segments: Laurus Generics, Laurus Synthesis, and Laurus Bio. The Laurus Generics segment comprises API and FDF-Development, manufacture and sale of APIs and advanced intermediates and oral solid formulations/FDF. Laurus Synthesis segment comprises key starting materials (KSM), intermediates and APIs for new chemical entities (NCEs). Laurus Bio segment comprises recombinant products, animal origin free products for safer and viral free bio manufacturing. The Company operates through two geographical segments: Revenue from customers within India-Domestic, and Revenue from customers outside India-Exports. The Company sell its APIs in 56 countries.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
425.9 INR
Average target price
371.7 INR
Spread / Average Target
-12.72%
Consensus